Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Subcutaneous Induction Therapy in Moderately to Severely Active Ulcerative Colitis
NCT05528510Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of guselkumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Sep 2022; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05528510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528510.